I. MODIFIED AGREEMENTS
Biotech Co.* (Country; Symbol) Pharma Co.

(Country)

 Change from original

agreement

 Terms/Details (Date)
Ambit Biosciences Corp.* Bristol-Myers Squibb Co. Expanded kinase inhibitor discovery collaboration BMS will make an up-front payment, and Ambit will use its KinomeScan kinase profiling platform to screen BMS's kinase-focused library; Ambit also gets rights to certain BMS preclinical and clinical compounds (10/31)
Debiopharm Group SA* (Switzerland) Ipsen SA (France) Expanded agreement under which Ipsen commercializes prostate cancer drug Deca-peptyl Ipsen licensed rights to a Phase III sustained-release formulation of Decapeptyl for a minimum of five years after the current formulations go off patent in 2010 (10/31)
Depomed Inc. (DEPO) Watson Pharmaceuticals Inc. Expanded co-promotion agreement to grant Watson the right to promote Depomed's ProQuin XR in the obstetrics/gynecology specialty market area The agreement expands the relationship entered in July for the promotion to both urology and long-term care specialty areas in the U.S. (9/25)
Exelixis Inc. (EXEL) Bristol-Myers Squibb Co. Research collaboration to develop and commercialize drugs targeted against the liver X receptor The companies signed the potential $317.5M LXR agonist deal in December 2005; the extension provides Exelixis additional research funding of $7.5M, and extends the collaboration timeline through Jan. 12, 2009, with BMS retaining the option to add another year (9/21)
Idenix Pharmaceuticals Inc. (IDIX) Novartis AG (Switzerland) Modified agreement in which Novartis will take over all responsibility for Tyzeka It will pay Idenix royalties (9/28)
SGX Pharmaceuticals Inc. (SGXP) Novartis AG (Switzerland) Amended agreement to give SGX the right to develop and commercialize SGX393 outside of the collaboration It is subject to a reacquisition right of Novartis; financial terms remain unchanged (9/11)
TorreyPines Therapeutics Inc. (TPTX) Eisai Co. Ltd. (Japan) Extended research agreement focused on genetics of Alzheimer's disease TorreyPines will receive an up-front payment and continued research funding; Eisai retained exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research (9/25)
II. TERMINATED AGREEMENTS
Alnylam Pharmaceuticals Inc. (ALNY) Merck & Co. Inc. Terminated agreement that had given Merck access to Alnylam's intellectual property for current and future development programs The decision was made due to Merck's intentions of acquiring Alnylam's RNAi rival, Sirna Therapeutics Inc. (9/19)
Depomed Inc. (DEPO) King Pharmaceuticals Inc. Terminated promotion agreement for Glumetza to treat Type II diabetes King has paid Depomed termination and other fees of about $30M and Depomed will not pay King a promotion fee for the quarter ending Dec. 31 (10/30)
Jerini AG (Germany; BE:JI4) Abbott Laboratories Terminated agreement for Icatibant Abbot is paying Jerini an undisclosed termination fee, and Jerini will pay Abbott undisclosed sales royalties for 24 months following the launch of the product in North America
Kosan Biosciences Inc. (KOSN) Roche Holding AG (Switzerland) Terminated five-year collaboration to develop and commercialize epothilones The termination was driven by Roche's reprioritization of its research and development group (10/28)
Nektar Therapeutics Inc. (NKTR) Pfizer Inc. Terminated marketing agreement for Exubera Pfizer decided to drop the product after second quarter sales reached only $4M (10/18)
Paion AG (Germany; PK:PAIOF) Forest Laboratories Inc. Terminated development agreement for Paion's clot-busting stroke drug desmoteplase Forest returned North American rights, which it had gained through a 2004 agreement; the product had missed its endpoint in a Phase III trial (8/30)
Palatin Technologies Inc. (AMEX:PTN) King Pharmaceuticals Inc. Terminated development and marketing agreement on bremelanotide King returned all rights to Palatin after the FDA raised serious concerns about the acceptable benefit-risk ratio to support the progression of the product into Phase III studies for erectile dysfunction (9/10)
Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; BE = Berlin Stock Exchange; PK = Pink Sheets.